Prescription EPA & heart events
Does prescription EPA prevent cardiovascular events?
REDUCE-IT found fewer cardiovascular events with icosapent ethyl in selected statin-treated patients. The finding is specific to the prescription formulation and trial population.
Updated September 24, 2026 · Editorial attribution: PV Griscom, M.Sc. · Independent clinical review pending
The question behind the headline
8,179 high-risk adults on statins with elevated triglycerides; 4 g/day icosapent ethyl versus mineral oil.
What the finding does—and doesn’t—tell us
The primary endpoint occurred in 17.2% versus 22.0% over a median 4.9 years. Atrial-fibrillation hospitalization was higher. STRENGTH tested a different formulation and found no primary-endpoint benefit.
Read the underlying research.
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. · 2019 ↗
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. · 2020 ↗
Selected sources, not an exhaustive reference list. Rating draws on published results and review summaries; no independent full systematic review has been conducted. Source publication dates may precede this page’s update date.
Three questions to take forward
- Was the study population similar to the person or situation I have in mind?
- Did it measure an outcome people feel or experience, or only a laboratory marker?
- How do formulation, usual care, absolute benefit and adverse effects change the interpretation?
Study doses describe experiments; they are not personal dosing advice. Explore safety and limitations ↗